Ellume is making news and these ASX shares are surging, again

You can't buy shares in Ellume on the ASX, but here's the next best.

| More on:
Woman prepares to insert a swab in her nose to test for COVID-19 at home.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unlisted company Ellume is making headlines again with reports claiming Australian governments are being lobbied to approve the use of at-home rapid COVID-19 tests.

While it would be the dream of many investors to see Ellume debut on the ASX, we have these shares to keep an eye on until then.

Quick refresher on Ellume

Ellume is a Brisbane-based developer of digitally enabled diagnostic products. Nowadays, however, it's most well known for its at-home rapid COVID-19 tests.

Ellume's rapid COVID-19 test was the first to receive emergency approval from the United States Food and Drug Administration (FDA).

As The Motley Fool has previously reported, the test developed by Ellume costs around US$30 and takes around 20 minutes to show a result.

It has a 94% success rate when detecting COVID-19. It also has a 96% success rate in detecting the virus is not present.

Why Ellume is boosting ASX shares

Right now, reports are swirling that both state and federal governments are facing pressure to approve the use of at-home COVID-19 tests like Ellume's.

However, as we reported here, there's a lot of pushback from government and experts.

But not all hope is lost. News of the unlisted company tends to boost a number of ASX listed shares.

AnteoTech Ltd (ASX: ADO)

Potentially the closest share to Ellume on the ASX is AnteoTech. Right now, shares in AnteoTech are trading for 8.89% more than their previous close. The AnteoTech share price is 25 cents.

One of AnteoTech's major customers is Ellume. Ellume uses AnteoTech's AnteoBind technology in their rapid COVID-19 tests.

AnteoTech generally moves when we hear about Ellume.

Atomo Diagnostics Ltd (ASX: AT1)

Another share that's been boosted by today's news is Atomo Diagnostics.

Atomo also creates at-home COVID-19 rapid tests. The company partners with Access Bio to bring its integrated device together with Access Bio's rapid COVID-19 antibody test strips. The resulting at-home rapid test is named CareStart COVID-19 IgM/IgG.

The CareStart COVID-19 lgM/lgG received FDA emergency use approval last month.

The Atomo share price is currently 10% higher, with shares in the company trading for 22 cents apiece.

Memphasys Ltd (ASX: MEM)

Memphasys is another biotech share that the market tends to get excited about when word of Ellume hits the streets. The Memphasys share price is 4.62% higher today, trading at 6.8 cents.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. 

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »